Correlation Between Serum Lipoamide Dehydrogenase Activity and Phosphatidylcholine Therapy in Friedreich’s Ataxia

S.B. MELANÇON, G. FONTAINE, G. GEOFFROY, M. VANASSE, L. DALLAIRE, M. POTIER

SUMMARY: Serum lipoamide dehydrogenase activity and kinetics were studied in nine patients with Friedreich’s ataxia before and after therapy with oral lecithin. Results disclosed a significant reduction in LAD inhibition by NADH in all patients after therapy. Three patients normalized their increased Km for lipoamide and one patient showed the opposite results after therapy.

RÉSUMÉ: Nous avons étudié les constantes d'affinité et les vécéités maximales de l'enzyme lipoamide dehydrogénase dans le sérum de neuf patients atteints de l'Ataxie de Friedreich et traités à la lécithine. Deux patients se sont retirés de l'étude après un mois à cause du peu d'effet de la médication. Les sept autres patients ainsi qu'un huitième cas éNavigué plus tardivement, ont manifesté une amélioration subjective et objective de leur résistance physique aprètrois mois de traitement. Nous avons observé une normalisation du Km lipoamide chez trois d'entre eux et une élévation anormale de ce paramètre chez un quatrième. Tous les patients qui ont terminé l'épreuve thérapeutique avaient aussi normalisé leur niveau élevé d'inhibition de la LAD sérique par le NADH.
C'est donc la première fois que des mesures biochimiques viennent supporter des critères cliniques subjectifs dans l'évaluation de l'effet de la lécithine dans l'Ataxie de Friedreich.

From the Centre de Recherche Pédiafrique, Hôpital Ste-Justine; Département de Pédiatrie et Neurologie, Université de Montréal.

Reprint requests for the complete supplement on Friedreich's ataxia (Phase three) to: Dr. André Barbeau, Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal, Quebec, Canada, H2W 1R7.
participated in this study on a voluntary basis. No attempts were made to match patients and controls for age, sex or severity of the disease. The control group was heterogeneous and included seven healthy laboratory technicians or physicians (22 to 37 years of age) and twelve friends or relatives of patients with F.A. (all under 21 years of age, except for two, aged 38 and 39 years) who certified not to have taken "lecithin" before. Fasting serum (10ml) obtained from controls and patients was frozen at -80°C in one ml aliquots and assayed within one month for lipoamide dehydrogenase activity (LAD). Repeat serum samples were obtained from seven of the nine original patients and one additional patient after three months on oral phosphatidyl choline (lecithine, LALCO, Ltd. Montréal) at a dose of 3.2 g three times a day. Four patients were also available for blood sampling one month after the start of lecithin and two of them elected not to pursue their treatment thereafter.

Measurement of LAD activity and kinetic studies were carried out using freshly thawed serum and freshly prepared reagents as previously suggested (Melançon et al. 1978b). Standard runs using freshly thawed serum from the same control individual were made before every determination of LAD activity. Optical density readings averaged .039 ± .003 units/10 min/0.05 ml of serum (Range, .032 - .044) for a total of forty LAD determinations over a period of three months. Total LAD activity in serum was determined according to Pelley et al. (1976). Kinetic studies were performed using lipoamide at concentrations of 0.4 mM to 6 mM and NAD at concentrations of 0.05 mM to 3.0 mM. Inhibition of LAD activity by added NADH (Ki) was estimated with NADH at concentrations of 0.1 mM to 0.4 mM. Michaelis-Menten constants (Km) were calculated by linear regression from the linear portion of Lineweaver-Burk plots. Maximal enzyme velocities (Vmax) were determined in the same manner and for the purpose of illustration, were reported in optical density units (O.D.). Conversion into LAD U/liter of serum was done by multiplying the O.D. by 322 x 10³.

RESULTS

Seven of the nine patients treated with lecithin reported some degree of clinical improvement. By standard neurological evaluation it was found that these patients had improved their muscular strength and physical resistance in a qualitative rather than quantitative manner. Two patients experienced subjective deterioration after one month of therapy and elected to cease their treatment.

The effects of lecithin on LAD activity and kinetics in serum of patients with F.A. are illustrated in figures 1 and 2. The most striking effects appeared to be the reduction in Km and Vmax of LAD towards lipoamide in three patients (fig. 1 center and right) and the statistically significant reduction in LAD inhibition by NADH (fig. 2 right and table I) in patients with F.A. after three months of lecithin therapy.

The mean activity of LAD in serum as function of age of patient and controls is illustrated in figure 3.

DISCUSSION

Our results provide some evidence that the subjective clinical improvement observed with lecithin in patients with F.A. may occur through biochemical changes other than previously thought. We presume with others (Growdon et al. 1977) that part of the clinical success was due to an improved availability of acetylcholine from exogenous doses of choline precursor (lecithin). However, we have evidence that lecithin or some unknown metabolite of lecithin displayed some action prior to acetylcholine synthesis and possibly at the enzyme level itself.

The exact origin of LAD in serum is still unknown, although Pelley et al. (1976) provided evidence that liver could account for most of the enzyme recovered in serum. Our kinetic studies on serum and previous work in fibroblasts (Melançon et al. 1978a, b) were not in favor of the presence of more than one component of LAD, as reported for platelets (Kark et al. 1978). However, three of our nine patients displayed higher than control Km for lipoamide before lecithin and one after lecithin (the only control subject with high Km for lipoamide was a 38-year-old apparently healthy cousin of two patients with F.A.).
These data would be in agreement with the results of Kark et al. (1980) who reported an increased Km for lipoamide (in platelets) in families of patients with a recessive form of ataxia. However, there is a marked difference between lipoamide Km values in platelets (low = 0.056 mM; high = 0.147 mM) and serum (0.73 mM) which prevent us from comparing the results in an adequate way.

The effect of lecithin on LAD inhibition by exogenous NADH cannot be adequately explained at the present time. This decrease in the concentration of NADH necessary to bring out a 50% lowering in serum LAD activity may be due to factors present in serum or to enzymatic changes. We have not yet attempted to elucidate the origin of this modification.

Another unexpected finding was disclosed when serum LAD activity were plotted according to age. It was found that serum LAD activity was higher in younger patients with F.A., than in older control subjects. This observation is, however, not incompatible with previous reports of a decreased serum LAD activity (Melançon et al. 1977; Filla et al. 1978) in older patients with F.A. We are presently investigating the effect of lecithin on LAD activity, enzyme kinetics and objective parameters of physical performance in patients with F.A. and age-matched controls in a double-blind study. We hope to be able to answer some of the previously discussed but unresolved questions at the completion of this second study.

**ACKNOWLEDGEMENTS**

This work was supported by l'Association Canadienne de l'Ataxie de Friedreich. We thank Solange Lebrun-St-Jacques for her help in obtaining blood samples and Diane Bernard for typing the manuscript.

**REFERENCES**


---

**TABLE I**

| EFFECT OF ORAL LECHITHIN ON SERUM LAD ACTIVITY AND KINETICS IN FRIEDREICH'S ATAXIA |
|-----------------------------------------------|-----------------------------------------------|
| CONTROLS no therapy (19)                     | FRIEDREICH'S ATAXIA before therapy (9)        |
| LAD (O.D.)                                    | post-therapy (8)                              |
| Km LIPOAMIDE (mM)                             |                                               |
| 0.75 ± 0.44                                   | 0.73 ± 0.66                                  | 0.48 ± 0.41                                  |
| V_max LIPOAMIDE (O.D.)                        |                                               |
| 0.38 ± 0.009                                  | 0.041 ± 0.018                                | 0.032 ± 0.011                                |
| Km NAD (mM)                                   |                                               |
| 0.085 ± 0.028                                 | 0.111 ± 0.049                                | 0.076 ± 0.032                                |
| V_max NAD (O.D.)                              |                                               |
| 0.037 ± 0.005                                 | 0.041 ± 0.010                                | 0.040 ± 0.011                                |
| Ki NADH (mM)                                  |                                               |
| 0.28 ± 0.07                                   | *0.38 ± 0.02                                 | 0.26 ± 0.07                                  |

*: p < 0.05 for difference from controls (T-test of Welch) and from post-therapy (Student t test).


